Komori
Takara Bio (4974) · InitiativeFirst stated

Clinical Development with a View to Using the Conditional and Time-Limited Approval System

First written in FY2016. . Latest entry: FY2016.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Use of the Conditional and Time-Limited Approval System for Regenerative Medicine ProductsA theme 3 companies write about · 0 as a headwind · 3 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2016First statedAnnual report

    「特に国内においては、平成26年11月に施行された「医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律」により新たに導入された再生医療等製品の「条件及び期限付承認制度」等の諸制度の利用も視野に入れ、臨床開発を積極的に推進してまいります。」

    国内の再生医療等製品制度を臨床開発の手段として検討している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Takara Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Clinical Development with a View to Using the Conditional and Time-Limited Approval System | TAKARA BIO INC. (4974) | Komori